ArticleJournal of molecular histology2025
Arsenic-induced neurocardiac toxicity and protective role of Resveratrol: histopathological and molecular insights.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arsenic toxicity is a global health problem chiefly targeting soft tissues of the body like the brain and heart. The major mechanism underlying arsenic-induced neurotoxicity is oxidative stress. Particularly, the neurons and cardiac myocytes show limitless susceptibility to oxidative stress. Herein, we examined the impact of prolonged arsenic exposure and resveratrol post-treatment on the cardiac and neuronal [Ventromedial hypothalamic nucleus (VMH)] morphology. Adult mice were segregated into control and experimental groups; controls received distilled water, while experimental groups received oral gavage of arsenic trioxide (ATO) at low (2 mg/kg bw) or high (4 mg/kg bw) doses for 45 days. Cardiac effects were assessed at the low dose (2 mg/kg bw), whereas neurological effects were evaluated at both low and high doses. Mice were sacrificed on day 45 to obtain perfusion-fixed hearts and brains for histological and morphometric studies. Long-term ATO exposure resulted in a higher heart-to-body weight ratio than controls, suggesting ATO-induced hypertrophy. Microscopic observations revealed a regular arrangement of cardiac muscle fibres, branching patterns of cardiomyocytes, and fibroblasts across all the treatment groups. However, increased cardiac myocyte diameter in ventricles and substantial fibrosis in vessel walls were noticed in ATO-alone exposed hearts relative to controls. Selective vulnerability of hypothalamic neurons following ATO exposure was evident by significant alterations in morphometric parameters (reduced cell density and soma size) in the VMH nucleus of animals receiving ATO (2 and 4 mg/kg) alone. These dramatic histopathological alterations were found to be restored after ATO + Res co-treatment. We also examined the expression of ER-α in the preoptic area of the hypothalamus and indicated downregulation of ER-α due to prolonged ATO exposure. Our findings highlight Resveratrol as a potent neurocardiac protector against ATO toxicity via estrogen signaling modulation, supporting its therapeutic potential in arsenic poisoning.
Indexed as
Identifiers
40392359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.